NDA 022128 · Viiv Hlthcare
Selzentry
Maraviroc · Oral · CCR5 Co-receptor Antagonist
NovelAccelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Oct 30, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Aug 6, 2007
Approved uses
6
Original approval plus efficacy supplements
Registered trials
146
32 Phase 3, 6 recruiting
FAERS reports
2,293
1,961 serious, 264 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY Hepatotoxicity has been reported with use of SELZENTRY. Severe rash or evidence of a systemic allergic reaction (e.g., fever, eosinophilia, or elevated IgE) prior to the development of hepatotoxicity may occur. Patients with signs or symptoms of hepatitis or allergic reaction following use of SELZENTRY should be evaluated immediately [see Warnings and Precautions ( 5.1 )] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. • Hepatotoxicity has been reported which may be preceded by severe rash or other features of a systemic allergic reaction (e.g., fever, eosinophilia, or elevated IgE). ( 5.1 ) • Immediately evaluate patients with signs or symptoms of hepatitis or allergic reaction. ( 5.1 )
What it is approved for
From the label in effect Nov 10, 2023.
SELZENTRY is indicated in combination with other antiretroviral agents for the treatment of only CCR5‑tropic human immunodeficiency virus type 1 (HIV‑1) infection in adult and pediatric patients weighing at least 2 kg. Limitations of Use • SELZENTRY is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1 [see Microbiology ( 12.4 )]. SELZENTRY is a CCR5 co-receptor antagonist indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2 kg. ( 1 ) Limitations of Use: • Not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1. ( 1 )
Mechanism: Maraviroc is an HIV-1 antiviral drug [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 30, 2020 Supplement 19 · Efficacy · priority review LetterLabelMedication Guide
- Nov 4, 2016 Supplement 17 · Efficacy · priority review LabelReview
- May 27, 2010 Supplement 4 · Efficacy LetterLabel
- Nov 20, 2009 Supplement 2 · Efficacy LetterLabel
- Nov 25, 2008 Supplement 1 · Efficacy Letter
- Aug 6, 2007 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalReviewLetterLabel
4 products under this application
- SELZENTRY · MARAVIROC 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- SELZENTRY · MARAVIROC 300MG · TABLET, ORAL · Prescription · TE AB
- SELZENTRY · MARAVIROC 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- SELZENTRY · MARAVIROC 150MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Maraviroc" as an intervention, any sponsor and status, largest first.
- Expanded Access Program for Maraviroc At Multiple CentersPivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT00426660 · 1,047 participants · Start Feb 2007 · Primary completion Jun 2010
Drug: maraviroc · For: HIV Infections
Sites: Birmingham, Alabama; Hobson City, Alabama; Tucson, Arizona · 361 sites in all
- Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/LamivudinePivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT00098293 · 916 participants · Start Nov 2004 · Primary completion Apr 2007
Drug: Maraviroc + Zidovudine/Lamivudine; Efavirenz + Zidovudine/Lamivudine and 1 more · For: HIV-1
Sites: Birmingham, Alabama; Beverly Hills, California; Los Angeles, California · 144 sites in all
- Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1Pivotal-lookingTerminated
ViiV HealthcareGSK (GSK)
NCT01345630 · 813 participants · Start Sep 2011 · Primary completion Aug 2013
Drug: Maraviroc; Emtricitabine/tenofovir and 3 more · For: HIV-1
Sites: Birmingham, Alabama; Hobson City, Alabama; Hayward, California · 177 sites in all
- Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT00708162 · 724 participants · Start Jul 2008 · Primary completion Dec 2010
Drug: Elvitegravir; Raltegravir and 3 more · For: HIV Infection
Sites: Phoenix, Arizona; Little Rock, Arkansas; Beverly Hills, California · 180 sites in all
- Effects of Maraviroc vs. Efavirenz on CD4/CD8 RatioPivotal-lookingCompleted
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalAcademic, hospital or other
NCT03178084 · 721 participants · Start Oct 15, 2014 · Primary completion Nov 5, 2016
Drug: Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID; Efavirenz QD + Zidovudine/Lamivudine BID and 1 more · For: HIV/AIDS
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05502341 · 689 participants · Start Aug 16, 2022 · Primary completion Sep 29, 2025
Drug: Bictegravir; Lenacapavir and 2 more · For: HIV-1-infection
Sites: Berkeley, California; Beverly Hills, California; Los Angeles, California · 94 sites in all
- Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDFPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT02121795 · 668 participants · Start May 6, 2014 · Primary completion Aug 12, 2015
Drug: FTC/TDF; F/TAF and 3 more · For: HIV-1 Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Beverly Hills, California · 78 sites in all
- Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected SubjectsPivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT00098306 · 601 participants · Start Nov 2004 · Primary completion Apr 2007
Drug: Maraviroc (UK-427,857); Optimized Background Therapy and 3 more · For: HIV Infections
Sites: Sacramento, California; San Francisco, California; Auroa, Colorado · 22 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- virologic failure141
- viral mutation identified128
- pathogen resistance125
- pain95
- anxiety94
- off label use94
- drug ineffective93
- drug interaction86
- drug resistance85
- emotional distress73
- nausea73
- treatment failure64
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 11 |
| 2008 | 86 |
| 2009 | 151 |
| 2010 | 164 |
| 2011 | 138 |
| 2012 | 156 |
| 2013 | 124 |
| 2014 | 120 |
| 2015 | 140 |
| 2016 | 185 |
| 2017 | 133 |
| 2018 | 128 |
| 2019 | 108 |
| 2020 | 118 |
| 2021 | 140 |
| 2022 | 120 |
| 2023 | 124 |
| 2024 | 64 |
| 2025 | 49 |
| 2026 | 34 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Selzentry (Maraviroc)
2024 spending
$4.1M
Beneficiaries
346
2,034 claims
Per beneficiary
$11,836
$27.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $43,522,989 |
| 2021 | $40,068,272 |
| 2022 | $27,060,225 |
| 2023 | $8,700,940 |
| 2024 | $4,095,168 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.
Gulick RM, Fatkenheuer G, Burnside R, et al. · J Acquir Immune Defic Syndr 2014 · Clinical Trial, Phase III, Randomized Controlled Trial
- Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
Kawana-Tachikawa A, Llibre JM, Bravo I, et al. · PLoS One 2014 · Clinical Trial, Phase III, Multicenter Study
- Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.
Huffman AP, Richman LP, Crisalli L, et al. · Biol Blood Marrow Transplant 2018 · Clinical Trial, Research Support, N.I.H., Extramural
- Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment.
Shikuma CM, Wojna V, De Gruttola V, et al. · AIDS 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
Stellbrink HJ, Le Fevre E, Carr A, et al. · AIDS 2016 · Clinical Trial, Phase III, Comparative Study
- Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.
Colbers A, Best B, Schalkwijk S, et al. · Clin Infect Dis 2015 · Clinical Trial, Phase IV, Multicenter Study
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.